Synlogic, Inc. (SYBX)

NASDAQ: SYBX · IEX Real-Time Price · USD
1.03
-0.04 (-3.30%)
Jun 29, 2022 11:13 AM EDT - Market open
-3.30%
Market Cap 72.01M
Revenue (ttm) 2.00M
Net Income (ttm) -61.29M
Shares Out 70.25M
EPS (ttm) -0.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,175
Open 1.07
Previous Close 1.06
Day's Range 1.00 - 1.07
52-Week Range 0.88 - 4.22
Beta 1.61
Analysts Buy
Price Target 7.75 (+656.1%)
Earnings Date Aug 11, 2022

About SYBX

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically abso... [Read more...]

Industry Biotechnology
CEO Aoife Brennan
Employees 84
Stock Exchange NASDAQ
Ticker Symbol SYBX
Full Company Profile

Financial Performance

In 2021, Synlogic's revenue was $1.75 million, an increase of 221.83% compared to the previous year's $545,000. Losses were -$60.56 million, 2.35% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for SYBX stock is "Buy." The 12-month stock price forecast is 7.75, which is an increase of 656.10% from the latest price.

Price Target
$7.75
(656.10% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Synlogic Announces Appointment of General Counsel and Corporate Secretary

CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its propri...

Synlogic to Present at the 2022 National PKU Alliance (NPKUA) Conference

VANCOUVER, Wash., June 28, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its propri...

Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation C...

BETHESDA, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprieta...

Synlogic, Inc. (SYBX) Reports Q1 Loss, Misses Revenue Estimates

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 4.35% and 51.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Synlogic Reports First Quarter 2022 Financial Results and Provides Business Update

- Clinical readouts anticipated for phenylketonuria (PKU), homocystinuria (HCU) and enteric hyperoxaluria programs in H2 2022 –

Synlogic Announces Data Presentations from Five Programs at the 2022 Synthetic Biology: Engineering, Evolution & Desi...

CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its propr...

Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs at the Society for Inherited Metabolic Disord...

CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its propr...

Synlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 22.22% and 1.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Synlogic Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

- Phenylketonuria (PKU) program on track for Phase 3 trial initiation in H2 2022 –

Synlogic Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast

CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its propr...

Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its propr...

What Makes Synlogic, Inc. (SYBX) a New Buy Stock

Synlogic, Inc. (SYBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Synlogic Presents Data Demonstrating Reductions in Plasma Phenylalanine Levels in Patients with Phenylketonuria Treat...

CAMBRIDGE, Mass., Nov. 22, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, today announced presentati...

Synlogic, Inc. (SYBX) Reports Q3 Loss, Tops Revenue Estimates

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 0.00% and 233.09%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Synlogic Reports Third Quarter Financial Results and Provides Business Update

CAMBRIDGE, Mass., Nov. 10, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, today reported financial r...

Synlogic Announces Presentation of Phenylketonuria Data at 14th International Congress of Inborn Errors of Metabolism...

CAMBRIDGE, Mass., Nov. 10, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced presentati...

Synlogic and Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine for the Treatment of Homocystinuria

CAMBRIDGE, Mass. and BOSTON, Nov. 9, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, and Ginkgo Biowo...

Other symbols: DNA

Synlogic Announces Third Quarter 2021 Conference Call & Participation in Upcoming Banking Conference

CAMBRIDGE, Mass., Nov. 2, 2021 /PRNewswire/ -- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Compa...

Synlogic Announces Nature Communications Publication Highlighting Use of Synthetic Biotic Platform to Optimize Therap...

CAMBRIDGE, Mass., Oct. 28, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced a publicat...

Synlogic Presents Data on Hyperoxaluria Program at American Society of Nephrology Kidney Week 2021

CAMBRIDGE, Mass., Oct. 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced two poster...

Synlogic Announces Nature Publication Demonstrating Novel Application of Synthetic Biotic Platform

CAMBRIDGE, Mass. , Oct. 12, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the publi...

Synlogic Appoints Molly Harper as Chief Business Officer

CAMBRIDGE, Mass., Sept. 27, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appoi...

Synlogic Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of ...

Synlogic Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has com...

Why Are Synlogic Shares Moving Higher Premarket Monday?

Synlogic Inc (NASDAQ: SYBX) has announced data from clinical studies evaluating SYNB1618 and SYNB1934 for phenylketonuria (PKU). PKU is a rare genetic disease that manifests at birth and is characterize...